Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how
well they work in treating participants with peripheral T-cell lymphoma that has come back or
that does not respond to treatment. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Romidepsin may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and romidepsin
may work better than pembrolizumab alone in treating participants with recurrent or
refractory peripheral T-cell lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI)